Parvovirus B19 Infection

No Results

No Results


Parvovirus B19 (B19V) is a single-stranded DNA virus of the family Parvoviridae and genus Erythrovirus. Although parvoviruses commonly cause disease in animals, it was only in 1975 that the first human pathogen of this family was discovered by Cossart and colleagues while screening normal blood bank donors’ sera for the hepatitis antigen (one of the donors’ serum samples was coded B19). [1, 2]

The presence of immunoglobulin antibodies to this virus in the serum of half of the adult population was established by epidemiological surveys, suggesting acquisition of immunity during childhood. Evidence of recent infection (viral antigen, immunoglobulin M [IgM]-specific antibodies to the virus) was first found in the blood of Jamaican children living in London, England, all of whom presented with transient aplastic crisis (TAC) of sickle cell disease. [3]

Later, Serjeant et al confirmed the close association of parvovirus and aplastic crisis in a large retrospective study of sera from sickle cell disease patients with this complication. [4] Later, human parvovirus B19 was shown to be the etiologic agent of erythema infectiosum in hematologically normal persons. [5, 6] Erythema infectiosum was originally named Fifth disease because it was the fifth of 6 classic exanthematous diseases of childhood to be described. Later, cases of nonimmune hydrops fetalis were reported when infection in a woman occurred during pregnancy [7] . Parvovirus B19 has also been associated with multiple other conditions. [8, 2, 5, 9, 10]

The images below provide examples of symptoms observed with parvovirus B19 infection.

The incubation period from infection to initial, nonspecific symptoms ranges from 4-14 days; but cases have been reported as long as 21 days after exposure. The rash and joint symptoms usually occur 2-3 weeks after initial infection. Patients are most contagious in the few days preceding rash. Patients with aplastic anemia are considered contagious before the onset of symptoms and for at least 1 week. [5, 9, 8, 11]

Parvovirus B19 has a unique tropism for human erythroid progenitor cells. The virus requires the P blood antigen receptor (also known as globoside) to enter the cell. Rare individuals who lack the P antigen are immune to parvovirus B19 infection. Once inside the host cell, viral DNA enters the nucleus. The 3′ end of the DNA strand folds back on itself, forming a hairpinlike bend that functions as a self-primer for viral DNA replication. The virus is cytotoxic to host cells. [2, 12] This, coupled with the tropism for rapidly dividing erythrocyte precursors (particularly pronormoblasts and normoblasts, wherein they replicate to high titers), leads to the suppression of erythrogenesis seen during infection. No reticulocytes (immature erythrocytes) are available to replace aging or damaged erythrocytes as they are cleared by the reticuloendothelial system. [5, 2]

Although decreases in hemoglobin levels of greater than 1 g/dL are rare in healthy children infected with parvovirus B19, decreases of 2-6 g/dL may be observed in patients with hemoglobinopathies or hemolytic anemias. Occasionally, the virus infects leukocytes (especially neutrophils). [13] Parvovirus B19 does not infect megakaryocytes; however, in vitro, parvovirus B19 proteins have a cytotoxic effect on megakaryocytes. Although B19V infection may manifest with pancytopenia, it is not believed to contribute significantly as an etiology of true aplastic anemia. [9, 11]

Fetal myocardial cells are known to express P antigen and may become infected with parvovirus B19. This may explain some of the direct myocardial effects seen in fetal infection. [2, 14]

United States

Parvovirus B19 infection is extremely common. Seropositivity rates are 5-10% among young children (aged 2-5 years), increasing to 50% by age 15 years and 60% by age 30 years. A small percentage of adults acquire infection every year, resulting in an incidence of approximately 90% in adults older than 60 years. [8, 6] The annual seroconversion rate among pregnant women without parvovirus B19 is 1.5%. [9]

Clinical cases of parvovirus B19 infection (erythema infectiosum) may be sporadic or may occur in outbreaks in the late winter through early spring. Attack rates during school outbreaks may be as high as 60%, [8] and secondary spread through nonimmune household contacts is common. Infection can be an occupational hazard in child care workers, with a rate of 20% reported in some studies. [9] A cyclic increase in the number of infections is also observed, peaking every 3-4 years. [8]


Parvovirus B19 infection is common worldwide. The age distribution is similar to that observed in the United States. A small number of groups, living in remote geographical locations, have not been exposed to human parvovirus. [2]

Parvovirus B19 infection in otherwise healthy children and adults has an extremely low mortality rate. [5, 2, 11]

Morbidity is as follows:

Erythema infectiosum (Fifth disease) is described in clinical manifestations below.

Polyarthropathy syndrome is mostly seen in adult women with acute infection. Patients develop acute symmetric arthritis affecting the small joints of the hands and feet, typically lasting for 1-3 weeks. In a small number, the arthritis may be prolonged, lasting for months. These symptoms can be confused with rheumatoid arthritis and further complicated by transient rheumatoid factor production during parvovirus B19 infection. [15] For this reason, parvovirus B19 infection should be considered in the differential diagnosis of newly diagnosed rheumatoid arthritis. Studies have not shown a causal link between parvovirus B19 infection and rheumatoid arthritis, and parvovirus B19 does not cause degenerative joint changes. [8]

In patients with hemoglobinopathies or hemolytic anemias, in whom the duration of erythrocyte survival is decreased, a decrease in the reticulocyte count to less than 1% (usually to 0%) may precipitate TAC. Such a crisis is characterized by profound anemia caused by a temporary halt in new erythrocyte production. [4] Abnormal erythrocytes, such as those associated with hemoglobinopathies, have a significantly shortened half-life because they are removed from circulation by the reticuloendothelial system. Any interruption in new erythrocyte production may trigger a crisis.

The bone marrow during TAC reveals an absence of erythroid precursors and the presence of striking giant pronormoblasts; rarely, necrosis may occur. [16] Parvovirus B19 is the only infectious cause of TAC known and has been shown to be the cause of aplastic crisis in over 80% of patients with sickle cell disease. [2, 8] .

Patients who are immunocompromised (eg, receiving chemotherapy or immunosuppressive drugs or have immune defects [congenital and acquired]) may develop chronic parvovirus B19 infection that results in chronic anemia. Pure red cell aplasia (PRAC) persists until the virus is cleared and should be distinguished from the transient anemia described above. [8, 5, 6, 10] Chronic parvovirus B19 infection in transplant recipients has been linked to anemia, other hematologic abnormalities, myocarditis, and pneumonitis. [17] Pediatric patients with hematologic malignancies and parvovirus B19 infection have suffered prolonged anemia that interferes with chemotherapy timing [18] .

Parvovirus B19 has been linked to other hematologic abnormalities. Thrombocytopenia, leukopenia, or both may be seen in acute infection, even in immunologically normal hosts. Cases of immune thrombocytopenic purpura, Henoch-Schönlein purpura, and the hemophagocytic syndrome have been attributed to parvovirus B19. However, transient erythroblastopenia of childhood and true aplastic anemia are not associated with infection. [8, 19, 11]

Hydrops fetalis, perhaps the most serious complication of parvovirus B19 infection, may occur when a nonimmune woman is infected, usually in the first 20 weeks of pregnancy.

Parvovirus B19 infection is the most common cause of nonimmune hydrops fetalis and can result in fetal death in 2-6% of cases. [9, 41]

As many as 50% of women of childbearing age may not be immune to parvovirus B19 and are susceptible to infection. [5] The seroconversion rate in the same group is 1.5% per year. [9] The vertical infection rate is estimated at 25-50%. The rate of fetal loss is estimated to be 1.6-9%. [5, 20, 21, 22] Of fetuses infected in the first half of pregnancy, 85% develop hydrops develops within 10 weeks (mean 6-7 wk). In one case series, no fetus infected after 21 weeks’ gestation developed severe anemia. [23]

The most critical gestational age appears to be 13-16 weeks’ gestation, when the fetus has the highest rates of hepatic hematopoiesis.

Historically, hydrops had a 30% mortality rate; however, newer data demonstrate a resolution of 94% of cases within 6-12 weeks and a mortality rate of less than 10% if the fetus can be supported by transfusion. [24]

Investigators have also called attention to the occurrence of severe anemia in fetuses with hydrops and suggest this may complicate the transfusion procedure. [23]

Intrauterine growth retardation, myocarditis, and pleural and pericardial effusions may also occur; however, parvovirus B19 is not associated with a congenital malformation. [9, 8, 14, 21]

Infection in the pregnant patient is further covered below.

A guideline reviewed the evidence relating to the effects of parvovirus B19 on the pregnant woman and fetus, and also the management of women who are exposed to, who are at risk of developing, or who develop parvovirus B19 infection in pregnancy. Investigation for parvovirus B19 infection was recommended apart from the standard workup for fetal hydrops or intrauterine fetal death. [25, 26]

No racial predilection is known.

In general, parvovirus B19 infection affects males and females in equal numbers. Adult females are more likely to develop postinfectious arthritis.

Parvovirus B19 infection is common in school-aged and younger children who attend daycare facilities. In general, children transmit the virus to parents and siblings. In young children, the antibody seroprevalence ranges from 5-10%. This increases to 50% in adolescents and approaches 90% in the elderly. [9, 2]

Cossart YE, Field AM, Cant B et al. Parvovirus-like particles in human sera. Lancet. 1975. 1:72.

Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004 Feb 5. 350(6):586-97. [Medline].

Pattison JR,Jones SE, Hodgson J et al. Parvovirus infections and hypoplastic crisis in sickle cell anaemia. Lancet. 1981. 1:664.

Serjeant GR, Topley JM, Mason K, Serjeant BE, Pattison JR, Jones SE, et al. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet. 1981 Sep 19. 2(8247):595-7.

Cherry JD, Schulte DJ. Human Parvovirus B19. Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL, eds. Feigin & Cherry’s Textbook of Pediatric Infectious Diseases. 6th ed. Philadelphia, PA: Saunders Elsevier; 2009. Vol 2: 1902-1920.

Servey JT, Reamy BV, Hodge J. Clinical presentations of parvovirus B19 infection. Am Fam Physician. 2007 Feb 1. 75(3):373-6. [Medline].

Anderson LJ, Hurwitz ES. Human parvovirus B19 and pregnancy. Clin Perinatol. 1988. 15:273.

Brown KE. Parvovirus B19. Bennet JE, Dolin R, Blaser M. Mandell, Douglas and Bennett’s Principals and Practice of Infectious Diseases. 8th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2015. Vol 2: 1840-1847.

American Academy of Pediatrics Committee on Infectious Diseases. Parvovirus B19. Kimberlin DW, Brady M, Jackson SA, Long SS, eds. 2015 Red Book: Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Peiatrics; 2015. 593-596.

Landry ML. Parvovirus B19. Microbiol Spectr. 2016 Jun. 4 (3):1-13. [Medline].

Schneider, E. Human Parvoviruses. Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases. 4th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2012. 1087-1091.

Burns K, Parish CR. Parvoviridae. Knipe DM, Howley PM, eds. Fields Virology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007. Vol 2: 65.

Mustafa MM, McClain KL. Diverse hematologic effects of parvovirus B19 infection. Pediatr Clin North Am. 1996 Jun. 43(3):809-21. [Medline].

Ergaz Z, Ornoy A. Parvovirus B19 in pregnancy. Reprod Toxicol. 2006 May. 21(4):421-35. [Medline].

Luzzi GA, Kurtz JB. Human parvovirus arthropathy and rheumatoid factor(Letter). Lancet. 1985. 1:1218.

Conrad ME, Studdard H et al. Case report: aplastic crisis in sickle cell disorders: bone marrow necrosis and human parvovirus infection. Am J Med Sci. 1988. 295:212.

Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis. 2006 Jul 1. 43(1):40-8. [Medline].

Lindblom A, Heyman M, Gustafsson I, Norbeck O, Kaldensjo T, Vernby A. Parvovirus B19 infection in children with acute lymphoblastic leukemia is associated with cytopenia resulting in prolonged interruptions of chemotherapy. Clin Infect Dis. 2008 Feb 15. 46(4):528-36. [Medline].

Young NS. Hematologic and hematopoietic consequences of B19 parvovirus infection. Semin Hematol. 1988. 25:159.

Mendelson E, Aboudy Y, Smetana Z, Tepperberg M, Grossman Z. Laboratory assessment and diagnosis of congenital viral infections:Rubella, cytomegalovirus (CMV), varicella-zoster virus (VZV),herpes simplex virus (HSV), parvovirus B19 andhuman immunodeficiency virus (HIV). Reprod Toxicol. 2006. 21:350-382.

Adler SP, Koch WC. Human Parvovirus Infections. Remington JS, Klein JO, Wilson CB, Baker CJ. Infectious Diseases of the Fetus and Newborn Infant. 6th ed. Philadelphia, PA: Saunders Elsevier; 2006. 868-892.

Tolfvenstam T, Broliden K. Parvovirus B19 infection. Semin Fetal Neonatal Med. 2009 Aug. 14(4):218-21. [Medline].

Simms RA, Liebling RE, Patel RR, et al. Management and outcome of pregnancies with parvovirus B19 infection over seven years in a tertiary fetal medicine unit. Fetal Diagn Ther. 2009. 25(4):373-8. [Medline].

Infections. Cunningham FG, Leveno KL, Bloom SL, Hauth JC, Gilstrap III LC, Wenstrom KD, eds. Williams Obstetrics. 22nd Ed. USA: McGraw-Hill; 2001. chap 58.

Crane J, Mundle W, Boucoiran I, Gagnon R, Bujold E, Basso M, et al. Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can. 2014 Dec. 36(12):1107-16. [Medline].

Ornoy A, Ergaz Z. Parvovirus B19 infection during pregnancy and risks to the fetus. Birth Defects Res. 2017 Mar 15. 109 (5):311-323. [Medline].

Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. Jrnl Internal Med. 2006. 260:285-304.

Hirai Y, Takeda Y. Atypical rashes in adult human Parvovirus B19 infection; atypical is typical. IDCases. 2016 Jun 23. 5:32-3. [Medline].

Grilli R, Izquierdo MJ, Farina MC, et al. Papular-purpuric “gloves and socks” syndrome: polymerase chain reaction demonstration of parvovirus B19 DNA in cutaneous lesions and sera. J Am Acad Dermatol. 1999 Nov. 41(5 Pt 1):793-6. [Medline].

Fretzayas A, Douros K, Moustaki M, Nicolaidou P. Papular-purpuric gloves and socks syndrome in children and adolescents. Pediatr Infect Dis J. 2009 Mar. 28(3):250-2. [Medline].

Tschope C, Bock CT, Kasner M, Noutsias M, Westermann D, Schwimmbeck PL. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation. 2005 Feb 22. 111(7):879-86. [Medline].

Douvoyiannis M, Litman N, Goldman DL. Neurologic manifestations associated with parvovirus B19 infection. Clin Infect Dis. 2009 Jun 15. 48(12):1713-23. [Medline].

Kleinman SH, Glynn SA, Lee TH, et al. A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood. 2009 Oct 22. 114(17):3677-83. [Medline]. [Full Text].

Bredl S, Plentz A, Wenzel JJ, Pfister H, Möst J, Modrow S. False-negative serology in patients with acute parvovirus B19 infection. J Clin Virol. 2011 Jun. 51(2):115-20. [Medline].

Soderlund-Venermo M, Hokynar K, Nieminen J et al. Undefined. Persistence of human parvovirus B 19 in human tissues. 2002. 50;:307-316.

Musiani M, Zerbini M et al.Gentilomi G et al. Parvovirus B19 clearance from peripheral blood after acute infection. J Infect Dis. 1995. 172:1360-1363.

Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM. Experimental parvoviral infection in humans. J Infect Dis. 1985 Aug. 152(2):257-65. [Medline].

Failey CK, Smoleniec JS et al. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B 19 infection. Lancet. 1995. 346:1335-1337.

[Guideline] Center for Disease control and Prevention. Risk associated with human parvovirus infection. MMWR. 1989. 38:81.

Ferrari B, Díaz MS, López M, Larralde M. Unusual skin manifestations associated with parvovirus B19 primary infection in children. Pediatr Dermatol. 2018 Nov. 35 (6):e341-e344. [Medline].

Bascietto F, Liberati M, Murgano D, Buca D, Iacovelli A, Flacco ME, et al. Outcome of fetuses with congenital parvovirus B19 infection: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018 Nov. 52 (5):569-576. [Medline].

David J Cennimo, MD, FAAP, FACP, AAHIVS Assistant Professor of Medicine and Pediatrics, Adult and Pediatric Infectious Diseases, Rutgers New Jersey Medical School; Hospital Epidemiologist and Co-Director of Antimicrobial Stewardship, University Hospital

David J Cennimo, MD, FAAP, FACP, AAHIVS is a member of the following medical societies: American Academy of HIV Medicine, American Academy of Pediatrics, American College of Physicians, American Medical Association, HIV Medicine Association, Infectious Diseases Society of America, Medical Society of New Jersey, Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Arry Dieudonne, MD Associate Professor of Pediatrics, Division of Pulmonology, Allergy, Immunology and Infectious Diseases, Rutgers New Jersey Medical School; Clinical Director, Francois-Xavier Bagnold Center for Children, University Hospital

Arry Dieudonne, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Joseph Domachowske, MD Professor of Pediatrics, Microbiology and Immunology, Department of Pediatrics, Division of Infectious Diseases, State University of New York Upstate Medical University

Joseph Domachowske, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa

Disclosure: Received research grant from: Pfizer;GlaxoSmithKline;AstraZeneca;Merck;American Academy of Pediatrics, Novavax, Regeneron, Diassess, Actelion<br/>Received income in an amount equal to or greater than $250 from: Sanofi Pasteur.

Russell W Steele, MD Clinical Professor, Tulane University School of Medicine; Staff Physician, Ochsner Clinic Foundation

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, Southern Medical Association

Disclosure: Nothing to disclose.

Glenn Fennelly, MD, MPH Director, Division of Infectious Diseases, Lewis M Fraad Department of Pediatrics, Jacobi Medical Center; Clinical Associate Professor of Pediatrics, Albert Einstein College of Medicine

Glenn Fennelly, MD, MPH is a member of the following medical societies: Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous coauthor Dennis Cunningham, MD, to the original writing and development of this article.

Parvovirus B19 Infection

Research & References of Parvovirus B19 Infection|A&C Accounting And Tax Services